PULMOZYME Israel - English - Ministry of Health

pulmozyme

roche pharmaceuticals (israel) ltd - recombinant human deoxyribonuclease - solution for inhalation - recombinant human deoxyribonuclease 1 mg/ml - dornase alfa (desoxyribonuclease) - dornase alfa (desoxyribonuclease) - management of cystic fibrosis not for patients under 5 years of age or with fvc<40% .

KOVALTRY 1000 IU Israel - English - Ministry of Health

kovaltry 1000 iu

bayer israel ltd - recombinant human coagulation factor viii - powder and solvent for solution for injection - recombinant human coagulation factor viii 1000 iu - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups.

KOVALTRY 2000 IU Israel - English - Ministry of Health

kovaltry 2000 iu

bayer israel ltd - recombinant human coagulation factor viii - powder and solvent for solution for injection - recombinant human coagulation factor viii 2000 iu - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups.

KOVALTRY 250 IU Israel - English - Ministry of Health

kovaltry 250 iu

bayer israel ltd - recombinant human coagulation factor viii - powder and solvent for solution for injection - recombinant human coagulation factor viii 250 iu - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups.

KOVALTRY 500 IU Israel - English - Ministry of Health

kovaltry 500 iu

bayer israel ltd - recombinant human coagulation factor viii - powder and solvent for solution for injection - recombinant human coagulation factor viii 500 iu - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups.

BEMFOLA follitropin alfa (rch) 450 IU/0.75 mL (33 microgram) solution for injection cartridge in a pre-filled pen Australia - English - Department of Health (Therapeutic Goods Administration)

bemfola follitropin alfa (rch) 450 iu/0.75 ml (33 microgram) solution for injection cartridge in a pre-filled pen

gedeon richter australia pty ltd - follitropin alfa, quantity: 450 iu - injection, solution - excipient ingredients: poloxamer; sucrose; dibasic sodium phosphate dihydrate; monobasic sodium phosphate dihydrate; methionine; phosphoric acid; thymidine; trypsin - in adult women:,- bemfola is indicated for the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated,- controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies,- bemfola in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level <1.2 iu/l.,in adult men:,- bemfola is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

BEMFOLA follitropin alfa (rch) 300 IU/0.5 mL (22 microgram) solution for injection cartridge in a pre-filled pen Australia - English - Department of Health (Therapeutic Goods Administration)

bemfola follitropin alfa (rch) 300 iu/0.5 ml (22 microgram) solution for injection cartridge in a pre-filled pen

gedeon richter australia pty ltd - follitropin alfa, quantity: 300 iu - injection, solution - excipient ingredients: poloxamer; sucrose; dibasic sodium phosphate dihydrate; monobasic sodium phosphate dihydrate; methionine; phosphoric acid; thymidine; trypsin - in adult women:,- bemfola is indicated for the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated,- controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies,- bemfola in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level <1.2 iu/l.,in adult men:,- bemfola is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

BEMFOLA follitropin alfa (rch) 225 IU/0.375 mL (16.5 microgram) solution for injection cartridge in a pre-filled pen Australia - English - Department of Health (Therapeutic Goods Administration)

bemfola follitropin alfa (rch) 225 iu/0.375 ml (16.5 microgram) solution for injection cartridge in a pre-filled pen

gedeon richter australia pty ltd - follitropin alfa, quantity: 225 iu - injection, solution - excipient ingredients: poloxamer; sucrose; dibasic sodium phosphate dihydrate; monobasic sodium phosphate dihydrate; methionine; phosphoric acid; thymidine; trypsin - in adult women:,- bemfola is indicated for the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated,- controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies,- bemfola in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level <1.2 iu/l.,in adult men:,- bemfola is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

BEMFOLA follitropin alfa (rch) 150 IU/0.25 mL (11 microgram) solution for injection cartridge in a pre-filled pen Australia - English - Department of Health (Therapeutic Goods Administration)

bemfola follitropin alfa (rch) 150 iu/0.25 ml (11 microgram) solution for injection cartridge in a pre-filled pen

gedeon richter australia pty ltd - follitropin alfa, quantity: 150 iu - injection, solution - excipient ingredients: poloxamer; sucrose; dibasic sodium phosphate dihydrate; monobasic sodium phosphate dihydrate; methionine; phosphoric acid; thymidine; trypsin - in adult women:,- bemfola is indicated for the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated,- controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies,- bemfola in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level <1.2 iu/l.,in adult men:,- bemfola is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

BEMFOLA follitropin alfa (rch) 75 IU/0.125 mL (5.5 microgram) solution for injection cartridge in a pre-filled pen Australia - English - Department of Health (Therapeutic Goods Administration)

bemfola follitropin alfa (rch) 75 iu/0.125 ml (5.5 microgram) solution for injection cartridge in a pre-filled pen

gedeon richter australia pty ltd - follitropin alfa, quantity: 75 iu - injection, solution - excipient ingredients: poloxamer; sucrose; dibasic sodium phosphate dihydrate; monobasic sodium phosphate dihydrate; methionine; phosphoric acid; thymidine; trypsin - in adult women:,- bemfola is indicated for the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated,- controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies,- bemfola in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level <1.2 iu/l.,in adult men:,- bemfola is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.